For families in remote villages across northeastern India, seeing a doctor often means long journeys over difficult terrain, lost daily wages, and sometimes, lifesaving treatment that comes too late.
In the next two decades, the global population over age 65 is expected to increase exponentially. With this aging population, we will see a rise in the development of chronic conditions like cardiovascular diseases and diabetes.
We’re incredibly proud of how our own healthcare heroes have worked tirelessly in the fight against COVID-19. Messages, like this one from Gov. Ralph Northam of Virginia, highlight the impact that we’re making.
Merck and Ridgeback Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for molnupiravir, an investigational oral antiviral (MK-4482, EIDD-2801).
One year ago, FedEx Express, a subsidiary of FedEx Corp. and the world’s largest express transportation company, delivered the first shipments of the COVID-19 vaccines to dosing centers in the United States.
RESOLVE, on behalf of a multi-sector consortium, announced today the launch of HealthGrid Sierra Leone, an initiative to provide sustainable electricity and other essential services to off-grid health facilities in Sierra Leone.
While coping with the effects of cancer during the holidays is difficult, we find hope in the research work being done at Alkermes to help expand the future of cancer treatment for patients and their families.
Merck and Ridgeback Biotherapeutics announced the New England Journal of Medicine has published findings from the Phase 3 MOVe-OUT trial evaluating molnupiravir, an investigational oral antiviral COVID-19 medicine.
Everyone’s financial journey is different. We make intentional efforts to meet the individual needs of clients and communities through a diverse range...
Highlighting the top news, commentary, and research for the week coming from SHQ. The highlights newsletter also spotlights one profiled organization...
